Search

Displaying results 6981 - 6990 of 7657 in total
  1. Drug

    LX-7101

    go.drugbank.com/drugs/DB16009
    Investigational

    LX-7101 is under investigation in clinical trial NCT01528111 (Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension).

  2. Drug

    PF-06882961

    go.drugbank.com/drugs/DB16043
    Investigational

    PF-06882961 is under investigation in clinical trial NCT03985293 (A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus).

  3. Drug

    AIM-102

    go.drugbank.com/drugs/DB16176
    Investigational

    AIM-102 is under investigation in clinical trial NCT01501942 (Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic

  4. Drug

    PF-06291874

    go.drugbank.com/drugs/DB15065
    Investigational

    PF-06291874 is under investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of PF-06291874 as Oral Monotherapy To Treat Adults With Type 2 Diabetes

  5. Drug

    YF087

    go.drugbank.com/drugs/DB33921
    Experimental

    YF087 is under investigation in clinical trial NCT07809607 (A Study to Evaluate YF087 in Subjects With MSI-H or dMMR Advanced Solid Tumors).

  6. Drug

    WX-554

    go.drugbank.com/drugs/DB21749
    Investigational

    WX-554 is under investigation in clinical trial NCT01581060 (Phase I/​II Dose-escalation Study to Investigate Safety and Pharmacokinetics/​ Pharmacodynamics of WX-554 in Patients With Solid Tumours).

  7. Drug

    Urolithin A

    go.drugbank.com/drugs/DB15464
    Experimental

    It has been demonstrated to stimulate mitophagy and improve muscle health in old animals and in preclinical models of aging.[A179494]

  8. Drug

    KAI-1455

    go.drugbank.com/drugs/DB06064
    Experimental

    In preclinical studies, KAI-1455 showed a dramatic reduction in infarct size when delivered prior to the ischemic insult. … KAI-1455 is a selective epsilon protein kinase C (εPKC) activator designed to reduce ischemic organ injury during procedures where blood supply may be compromised, such as coronary artery bypass grafting

  9. Drug

    Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine

    go.drugbank.com/drugs/DB16431
    Experimental

    Regarding this vaccine specifically, it stimulates the immune system to produce anti-receptor binding domain antibodies[A226593]. … Receptor binding domain SARS-CoV-2 Hepatitis B surface antigen virus-like particle vaccine (RBD SARS-CoV-2 HBsAg VLP vaccine), is a virus-like particle vaccine candidate where the RBD antigen is conjugated to

  10. Drug

    Saralasin

    go.drugbank.com/drugs/DB06763
    Experimental

    Categories: Agents Acting on the Renin-Angiotensin System